Showing 2281-2290 of 5909 results for "".
- Johnson & Johnson Presents New Data on ACUVUE OASYS MAX 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-presents-new-data-on-acuvue-oasys-max-1-day-contact-lenses/2482523/Johnson & Johnson will present data at Academy of Optometry 2024 on the ACUVUE OASYS MAX 1-Day family of contact lenses including contrast sensitivity, brightness of natural images, lens handling, and more. Data will also be presented on myopia management, use of digital technologie
- GenSight Biologics Publishes Meta-Analysis on Efficacy of Treatments for Leber Hereditary Optic Neuropathyhttps://modernod.com/news/gensight-biologics-publishes-meta-analysis-on-efficacy-of-treatments-for-leber-hereditary-optic-neuropathy/2482521/GenSight Biologics announced the publication of a meta-analysis evaluating visual outcomes in patients with Leber Hereditary Optic Neuropathy (LHON) due to the MT-ND4 mitochondrial gene mutation. This mutation, known as ND4-LHON, is the most common cause of the disease and is associated with the
- Study of Alkeus' Oral Gildeuretinol Demonstrate Trend in Slowing GA Progression and Visual Function Improvementhttps://modernod.com/news/study-of-alkeus-oral-gildeuretinol-demonstrate-significant-trend-in-slowing-ga-progression-and-visual-function-improvement/2482511/Alkeus Pharmaceuticals announced findings from its SAGA study, which evaluated the investigational oral therapy gildeuretinol (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study showed a statistically significant reduction in GA l
- SpyGlass Pharma Unveils Promising 18-Month Data from First-in-Human Study of Glaucoma Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-unveils-promising-18-month-data-from-first-in-human-study-of-glaucoma-drug-delivery-platform/2482500/SpyGlass Pharma presented 18-month follow-up data today from its first-in-human study of patients with glaucoma or ocular hypertension. The study evaluated the efficacy of the SpyGlass IOL-based drug delivery platform, which was implanted during cataract surgery. The results were shared at Eyecel
- AAO: Home OCT Device Improves Care for AMD Patients, Reduces Costs and Burdenhttps://modernod.com/news/aao-home-oct-device-improves-care-for-amd-patients-reduces-costs-and-burden/2482499/A newly approved home-based OCT device developed by Notel Vision is allowing patients to monitor their own eye health between appointments, providing physicians with crucial data without requiring in-office visits, according to an AAO news release. A study presented today at AAO 2024 suggest
- Alcon Collaborates with Eye Care Professionals to Identify and Address Unmet Needs in the Contact Lens Industryhttps://modernod.com/news/alcon-collaborates-with-eye-care-professionals-to-identify-and-address-unmet-needs-in-the-contact-lens-industry/2482485/A new Alcon program aims to identify and address current gaps in contact lens offerings by partnering with eye care professionals. With the new Alcon Innovator Program, 20 ‘innovators’ were selected to receive and offer their patients exclusive access to Alcon’s upcoming product
- New Study Unveils How Immune Cells Defend the Eye Against Inflammationhttps://modernod.com/news/new-study-unveils-how-immune-cells-defend-the-eye-against-inflammation/2482470/In a new study, researchers led by Sue Menko, PhD, of Thomas Jefferson University, have revealed how immune cells play a critical role in resolving inflammation on the surface of the eye’s lens. Published in The American Journal of
- Staar Opens New Experience Center to Meet Growing Surgeon Demandhttps://modernod.com/news/staar-opens-new-experience-center-to-meet-growing-surgeon-demand/2482452/Staar Surgical announced the expansion of its Staar Surgical Experience Center near John Wayne Airport (SNA) in Lake Forest, California. The new center aims to provide comprehensive, hands-on training and education in lens-based vision correction. Staar says the 
- Nicox and Glaukos Sign Global Licensing Deal for Glaucoma Drug Candidatehttps://modernod.com/news/nicox-and-glaukos-sign-global-licensing-deal-for-glaucoma-drug-candidate/2482451/Nicox has entered into an exclusive research and license option agreement with Glaukos for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor. The collaboration aims to accelerate research and development efforts for glaucoma and other serious ophth
- Ripple Therapeutics Partners with AbbVie to Develop Intracameral Implant for Glaucomahttps://modernod.com/news/ripple-therapeutics-partners-with-abbvie-to-develop-intracameral-implant-for-glaucoma/2482444/Ripple Therapeutics announced a collaboration and option-to-license agreement with AbbVie to advance the development of RTC-620, a fully biodegradable, sustained-release intracameral implant designed to reduce IOP in patients suffering from open-angle glaucoma (OAG) or ocular hypertensi